Portfolio News
2025/11/02
SinoMab (03681.HK) Wins the 2nd New Quality Productive Forces Enterprises Award
(2 November 2025 - Hong Kong) SinoMab BioScience Limited ("SinoMab" or the "Company", Stock
Code: 03681.HK) is pleased to announce that it has been awarded in the "Bio-pharmaceuticals,
Drug & Instrument Manufacturing, and Medical Service - Greater Bay Area New Quality
Productive Forces Enterprises Award " at the 2nd "Greater Bay Area New Quality Productive
Forces Enterprises Award".
"The Greater Bay Area New Quality Productive Forces Enterprise Award", co-organized by the Greater Bay Area Family Office Association, Hong Kong International Family Office Association, Hong Kong International Blockchain Finance Association, Greater Bay Area International Medical and Healthcare Industry Association, financial weekly Golden Venus, and family office magazine Family Office, is a highly prestigious accolade in the industry. It aims to recognize and encourage outstanding enterprises, thereby fostering innovation and development within the sector. New Quality Productive Forces refers to an emerging force that drives productivity development and economic growth through various means such as technological innovation, management innovation, and institutional innovation in specific historical periods. The Awards adopt New Quality Productive Forces as one of the evaluation criteria to acknowledge enterprises that demonstrate effective application of innovative technologies, enhanced production efficiency, optimized economic structure, and notable achievements in sustainable development.
SinoMab stood out from numerous outstanding enterprises with its exceptional performance in the biomedical field. The company has consistently focused on the R&D, production, and commercialization of antibody drugs, achieving continuous innovative breakthroughs in therapeutic areas such as autoimmune diseases. These efforts have not only provided patients with more effective treatment options but also infused robust innovative vitality into the entire biomedical industry. As a representative enterprise dedicated to innovative therapies for immune diseases, this accolade reflects the judging committee's high recognition of the company's innovative practices in the biomedical sector and its achievements in cultivating New Quality Productive Forces.
Dr. Leung Shui On, Chairman, Executive Director and Chief Executive Officer of SinoMab, noted, "This award recognizes the company's achievements in developing New Quality Productive Forces. Moving forward, we will continue to deepen our dedication to the biomedical field, driving progress through innovation and contributing more to the advancement of the industry and societal health. At the same time, we look forward to collaborating with partners in the Greater Bay Area to jointly promote the vigorous development of New Quality Productive Forces in the biomedical sector."
"The Greater Bay Area New Quality Productive Forces Enterprise Award", co-organized by the Greater Bay Area Family Office Association, Hong Kong International Family Office Association, Hong Kong International Blockchain Finance Association, Greater Bay Area International Medical and Healthcare Industry Association, financial weekly Golden Venus, and family office magazine Family Office, is a highly prestigious accolade in the industry. It aims to recognize and encourage outstanding enterprises, thereby fostering innovation and development within the sector. New Quality Productive Forces refers to an emerging force that drives productivity development and economic growth through various means such as technological innovation, management innovation, and institutional innovation in specific historical periods. The Awards adopt New Quality Productive Forces as one of the evaluation criteria to acknowledge enterprises that demonstrate effective application of innovative technologies, enhanced production efficiency, optimized economic structure, and notable achievements in sustainable development.
SinoMab stood out from numerous outstanding enterprises with its exceptional performance in the biomedical field. The company has consistently focused on the R&D, production, and commercialization of antibody drugs, achieving continuous innovative breakthroughs in therapeutic areas such as autoimmune diseases. These efforts have not only provided patients with more effective treatment options but also infused robust innovative vitality into the entire biomedical industry. As a representative enterprise dedicated to innovative therapies for immune diseases, this accolade reflects the judging committee's high recognition of the company's innovative practices in the biomedical sector and its achievements in cultivating New Quality Productive Forces.
Dr. Leung Shui On, Chairman, Executive Director and Chief Executive Officer of SinoMab, noted, "This award recognizes the company's achievements in developing New Quality Productive Forces. Moving forward, we will continue to deepen our dedication to the biomedical field, driving progress through innovation and contributing more to the advancement of the industry and societal health. At the same time, we look forward to collaborating with partners in the Greater Bay Area to jointly promote the vigorous development of New Quality Productive Forces in the biomedical sector."
